

Cytokinetics (NASDAQ:CYTK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of Cytokinetics (NASDAQ:CYTK) through any online brokerage.
Other companies in Cytokinetics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Cytokinetics has a consensus price target of $100.08.
The stock price for Cytokinetics (NASDAQ: CYTK) is $54.02 last updated November 6, 2026 at 6:43 PM EST.
There are no upcoming dividends for Cytokinetics.
Cytokinetics does not have any upcoming earnings scheduled.
There is no upcoming split for Cytokinetics.
Cytokinetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle...